Showing 2551-2560 of 5621 results for "".
- FDA Grants Orphan Drug Designation for Neurophth Therapeutics’ Gene Therapy for LHONhttps://modernod.com/news/fda-grants-orphan-drug-designation-for-neurophth-therapeutics-gene-therapy-for-lhon/2478326/Neurophth Therapeutics announced that its leading candidate, NR082, was granted an orphan drug designation (ODD) by the FDA for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) associated with ND4 mutation. LHON is a maternall
- Fauci Offers Defense of Why Americans Can Trust the Approval Process for a Potential COVID-19 Vaccinehttps://modernod.com/news/fauci-offers-defense-of-why-americans-can-trust-the-approval-process-for-a-potential-covid-19-vaccine/2478314/A potential COVID-19 vaccine is likely to approved in November or December, but the announcement of any such vaccine will not be based in any way on a political timeline, infectious disease expert Anthony Fauci, MD, said Tuesday evening during The Atlantic Festival, according to a FierceHealthcar
- Gyroscope Therapeutics Granted FDA Fast Track Designation for Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-granted-fda-fast-track-designation-for-investigational-gene-therapy-for-dry-amd/2478305/Gyroscope Therapeutics announced that the FDA has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is i
- Analysis: Ambulatory Surgery Centers Reduce Medicare Costs by More than $4 Billion Each Yearhttps://modernod.com/news/analysis-ambulatory-surgery-centers-reduce-medicare-costs-by-more-than-4-billion-each-year/2478306/New analysis of Medicare payment data shows that ambulatory surgery centers (ASC) reduced Medicare costs by $28.7 billion from 2011 through 2018 by providing services to beneficiaries that otherwise would have been provided in higher-cost hospital outpatient departments (HOPD), according to the A
- Keeler Partners With Medical Device Maker Olleyeshttps://modernod.com/news/keeler-partners-with-medical-device-maker-olleyes/2478278/Keeler has announced a partnership with Olleyes, a developer of eye care-based office and home-based diagnostic products. Terms of the deal were not disclosed. Olleyes is the maker of VisuALL VRP (Virtual Reality Perimetry), a platform designed for standardized and mobile assessment
- First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Post-Surgical Ocular Inflammation and Pain in Childrenhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-post-surgical-ocular-inflammation-and-pain-in-children/2478274/Ocular Therapeutix announced that it has dosed the first patients in a phase 3 clinical trial of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain in children following cataract surgery. “We are pleased to announce the start o
- Visible Genomics Launches DNA Age-Related Macular Degeneration Testinghttps://modernod.com/news/visible-genomics-launches-dna-age-related-macular-degeneration-testing/2478264/Visible Genomics, a Chicago-area genetics testing company, has announced the launch of a new noninvasive genetic eye test that the company says determines a patient’s likelihood of contracting age-related macular degeneration (AMD). While it’s estimated that up to 70% of AMD cases are due
- AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trialhttps://modernod.com/news/agtc-provides-trial-design-update-for-its-phase-2-3-xlrp-clinical-trial/2478261/Applied Genetic Technologies Corporation provided additional information about the proposed design of the planned phase 2/3 trial for its X-linked retinitis pigmentosa (XLRP) clinical program, which is expected to commence in the first quarter of 2021, and new preliminary data on
- Zeiss Launches “Vision in County” Cataract Development Program in Shandong, Chinahttps://modernod.com/news/zeiss-launches-vision-in-county-cataract-development-program-in-shandong-china/2478256/The “Vision in County” Cataract Development Program by Zeiss was officially launched in Shandong, China on September 3, 2020. At the event, the first training base was established in the Affiliated Eye Hospital of
- Nearly One Quarter of Chinese Children Hospitalized With COVID-19 Developed Eye Symptomshttps://modernod.com/news/nearly-one-quarter-of-chinese-children-hospitalized-with-covid-19-developed-eye-symptoms/2478244/Among Chinese children hospitalized for COVID-19, nearly a quarter developed ocular symptoms, a new study finds, Reuters reported. Most children developed eye symptoms later in the disease, but in nine, ocular manifestations were the first